Antigenics raises funds for Russia launch of Oncophage - 10 April 2008

A day after seeing its stock soar following the approval of its cancer vaccine Oncophage in Russia, the USA's Antigenics is planning a private placement to raise $21 million to help finance its launch. The stock climbed over 20% to $3.03 on the news that Antigenics has been given the green light by Russian regulators to market the kidney cancer vaccine Oncophage (vitespen). That news has now been followed by a deal to sell seven million shares priced at $3.00 each. Investors will also receive five-year warrants to purchase up to seven million additional shares at $3.75 per share. ...... Source : http://pharmatimes.com